BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30073902)

  • 1. The safety of ramucirumab for the treatment of colorectal cancer.
    Noguerido A; Mulet-Margalef N; Matos I; Ros J; Argilés G; Élez E; Tabernero J
    Expert Opin Drug Saf; 2018 Sep; 17(9):945-951. PubMed ID: 30073902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
    Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
    Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
    Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
    Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
    Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
    Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.
    Gambardella V; Tarazona N; Cejalvo JM; Roselló S; Cervantes A
    Expert Opin Drug Metab Toxicol; 2016; 12(4):449-56. PubMed ID: 26895445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of monoclonal antibodies for treatment of colorectal cancer.
    Berger MD; Lenz HJ
    Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of nintedanib in treating colorectal cancer.
    Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
    Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
    Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials.
    Matos I; Noguerido A; Ros J; Mulet N; Argilés G; Elez É; Tabernero J
    Expert Opin Investig Drugs; 2019 May; 28(5):463-471. PubMed ID: 30905200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic Therapy in Colorectal Cancer.
    Mody K; Baldeo C; Bekaii-Saab T
    Cancer J; 2018; 24(4):165-170. PubMed ID: 30119079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer.
    Takeda K; Daga H
    Expert Opin Biol Ther; 2016 Dec; 16(12):1541-1547. PubMed ID: 27737562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
    Saif MW
    Expert Opin Biol Ther; 2013 Nov; 13(11):1489-93. PubMed ID: 24050123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on panitumumab in metastatic colorectal cancer.
    Keating GM
    BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramucirumab: the long and winding road toward being an option for mCRC treatment.
    Debeuckelaere C; Murgioni S; Lonardi S; Girardi N; Alberti G; Fano C; Gallimberti S; Magro C; Ahcene-Djaballah S; Daniel F; Fassan M; Prenen H; Loupakis F
    Expert Opin Biol Ther; 2019 May; 19(5):399-409. PubMed ID: 30917706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
    Lee JJ; Chu E
    Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy.
    Lim YH; Odell ID; Ko CJ; Choate KA
    JAMA Dermatol; 2015 Nov; 151(11):1240-3. PubMed ID: 26422291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis inhibitors in early development for gastric cancer.
    Pinto MP; Owen GI; Retamal I; Garrido M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1007-1017. PubMed ID: 28770623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
    Garrido M
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.